Controlled Substance Telemedicine: What Providers Need to Know About DEA Compliance
Prescribing a Schedule II drug over a video visit carries a different level of regulatory weight than almost anything else telemedicine touches. The underlying law, the Ryan Haight Online Pharmacy Consumer Protection Act, was written in 2008 to require an in-person medical exam before a controlled substance could be prescribed remotely. Every telemedicine flexibility providers rely on today exists because DEA and HHS have repeatedly suspended that requirement on a temporary basis, and providers building a prescribing practice around those suspensions need to understand exactly how temporary “temporary” still is.
Where The Rule Actually Stands Right Now
DEA and HHS issued a fourth temporary extension of the COVID-era telemedicine prescribing flexibilities, effective January 1, 2026, and running through December 31, 2026. Under this extension, licensed practitioners can prescribe Schedule II through V controlled substances via telemedicine, including to patients they have never examined in person, without triggering the Ryan Haight in-person exam requirement. Audio-only telehealth also remains permitted for prescribing medications used to treat opioid use disorder. This is the same basic framework providers have operated under since 2023, just extended again rather than made permanent.
Why This Still Counts As Temporary
DEA has a proposed rule sitting on the table that would replace these rolling extensions with something permanent: a Special Registration for Telemedicine. Under the proposal, practitioners could obtain a special registration allowing them to prescribe Schedule III through V, and in narrower circumstances Schedule II, medications via telemedicine on an ongoing basis, with a proposed $50 fee for individual clinicians and $888 for telemedicine platforms. That rule has not been finalized. The agency has extended the temporary flexibilities four times now rather than commit to the special registration framework, and there is no guarantee the next extension arrives before the current one lapses. Practices that build controlled substance prescribing into their business model without a contingency plan are making a bet on a regulatory process that has, so far, only ever bought itself a few more months at a time.
What The Extension Does Not Change
The federal flexibility gets most of the attention, but it only removes one requirement: the in-person exam. Everything else about prescribing a controlled substance still applies exactly as it did before telemedicine flexibilities existed. Providers still need to be licensed, registered, or otherwise authorized to practice in the state where the patient is physically located at the time of the visit. Providers still need a valid DEA registration tied to a legitimate practice location in that state. State prescription drug monitoring program requirements still apply, and state-level prescribing rules around documentation, informed consent, and continuing education haven’t gone anywhere. The federal extension buys time on one narrow point of friction. It does not substitute for state compliance.
Arizona’s Layer On Top Of The Federal Rule
Providers treating patients physically located in Arizona need to register with Arizona’s controlled substances prescription monitoring program before writing that first controlled substance prescription, separate from any DEA registration already held. Telemedicine visits in Arizona are subject to the same prescribing, dispensing, and informed consent laws that govern in-person care, which means a provider needs verbal or written informed consent from the patient, or their health care decision maker, before delivering care through telemedicine. Any health professional authorized to prescribe Schedule II controlled substances in Arizona also has to complete a minimum of three hours of opioid-related, substance use disorder-related, or addiction-related continuing education each license renewal cycle. None of these requirements are waived by the federal telemedicine extension. They sit alongside it.
Getting The Practical Pieces In Place
For a telemedicine practice adding Arizona patients to a controlled substance prescribing panel, the checklist looks something like this: hold or register for the appropriate Arizona license or telehealth registration, register separately with the Arizona controlled substances prescription monitoring program, maintain a DEA registration tied to a real Arizona practice address rather than a home address or a P.O. box, build informed consent into the telemedicine intake workflow, and track the continuing education requirement alongside normal license renewal. None of this is exotic. It’s the same discipline any prescribing practice needs, applied to a state that happens to be a popular expansion target for telemedicine groups right now.
Providers navigating Arizona’s registration and address requirements for controlled substance prescribing don’t need to open a full clinical office to satisfy them. Viva MedSuites provides a qualified medical address in Scottsdale and Mesa that telemedicine practices use to meet DEA registration, state licensing, and Medicare enrollment requirements, with telemedicine memberships starting at $199 a month. If your practice is adding Arizona to its coverage and needs the address piece sorted out correctly the first time, visit vivamedsuites.com/telemedicine-az-address/ or call 480-616-2400.
John Groberg is the founder of Viva MedSuites, Arizona’s largest medical coworking community, with locations in Scottsdale and Mesa serving independent practitioners since 2017.
Viva MedSuites
Email: john@vivamedsuites.com
Website: www.vivamedsuites.com
Mesa Location
1910 S. Stapley Dr. Suite 120
Mesa, AZ 85204
Office: 480-616-2400
Scottsdale Location
9700 N. 91st St. Suite A-115
Scottsdale, AZ 85258
Office: 480-616-2400
